RFA-NS-25-022: BRAIN Initiative UH3 Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System

RFA-NS-25-022: BRAIN Initiative UH3 Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System

Key details

This opportunity is a strong fit for teams that already have a validated device concept and need a structured, federally supported route for translating it into early human studies with strong oversight requirements. It is designed for projects beyond bench and preclinical validation, where the biggest question is whether the device performs and can be advanced toward real-world clinical use.

What this NOFO is funding

The notice is explicit that this is part of the NIH BRAIN Initiative and that it prioritizes significant-risk clinical studies of next-generation neuro devices in the human central nervous system. These studies are milestone-driven, and the funding mechanism is intended to support projects that can provide data not available from non-clinical work.

The NOFO includes these major principles:

• The work should advance recording and/or modulation tools for central nervous system disorders or for understanding human brain function.
• Projects should be early stage but sufficiently mature to move into human testing and to generate meaningful evidence.
• The NOFO supports projects that can improve both technical performance and scientific knowledge of device mechanisms.
• It is oriented toward devices that are novel enough to require careful evaluation and structured go/no-go milestones.
• It is open to proposals with or without a clinical trial design, though clinical trial applications are explicitly allowed.

The opportunity references a public-private pathway, the BRAIN Public-Private Partnership (PPP), as a mechanism to lower barriers for partnerships with device manufacturers and to reduce the burden around device access and preliminary data. However, using the PPP is optional. Teams may also apply if they have existing manufacturer collaborations or are developing their own devices.

The project stage is important here. NIH already has UG3 and UH3 versions for this pathway. This NOFO is the UH3 clinical stage, intended to extend and test concepts where preclinical and regulatory positioning already exists. The companion structure is one reason this NOFO is often interpreted as part of a multi-stage translational funnel rather than a standalone pilot.

What kind of applicants are in scope

Broad organizational eligibility

The NOFO includes a wide set of eligible organizations:

• Public and private higher education institutions
• Nonprofits with and without 501(c)(3) status
• For-profit entities, including small businesses
• Local and federal governments and related entities
• Other specific organizational types listed as eligible U.S. organization categories

One important exclusion is explicit: non-domestic foreign organizations are not eligible. U.S. institutions can involve foreign components, but the organization submitting the application must be domestic and properly registered.

Who this is likely for

This NOFO is likely most relevant for:

1. Principal investigator-led device groups that can connect engineering science, clinical expertise, and regulatory strategy in one plan.
2. teams proposing first-in-human or early-stage human studies with a device already at proof-of-concept.
3. investigators and organizations that can support milestones, data plans, and post-award reporting with a strong compliance structure.
4. groups that can demonstrate engagement with patient stakeholders, clinical endpoints, and clear path to translation.

What is not a fit

Projects that are not a good match include:

• ideas that are still at basic discovery with no planned clinical path
• low-risk device studies that do not require the IDE framework the NOFO is designed around
• teams that cannot sustain the required documentation and milestone accountability
• applicants that cannot complete NIH and related registrations before submission

Eligibility, registrations, and compliance baseline

The NOFO is strict on process. It repeatedly states that incomplete or nonresponsive applications can be removed from review.

You should be prepared to meet these baseline requirements:

• SAM registration complete
• eRA Commons registration complete and PI profile(s) set
• Grants.gov registration complete
• Active UEI and signing official/PD PI role arrangements in place
• Compliance with NIH instructions in the How to Apply - Application Guide as modified by NOFO-specific rules

The NOFO also notes that applicants are encouraged to consult the program staff well before the deadline, ideally around 12 weeks earlier, because this is a cooperative agreement with milestone negotiation and scientific programmatic interaction.

A practical rule from the NOFO: if an item is described as required, missing attachments or formatting issues can be treated as grounds for delayed processing or non-responsiveness.

Key materials and attachment requirements that usually cause failures

This NOFO has unusually concrete requirements in both structure and content. The biggest compliance risks are around required attachments and study planning.

Must-have attachments and forms

The NOFO requires a number of materials in the application package, including:

• Gantt chart (1 page max), named Gantt.pdf in the package.
• IP Strategy attachment (3 pages max), named IP Strategy.pdf.
• Needs Assessment attachment (3 pages max), named Needs Assessment.pdf.
• Milestone and timeline sections and associated materials integrated with forms and PHS Human Subjects information.
• Neuroethics and DMS-plan-related content in the human subjects structure.
• Team Management Plan (2 pages max) and often strong letters of support.
• FDA correspondence section if appropriate.

How reviewers and program staff evaluate planning

The NOFO repeatedly says applications without milestones that support go/no-go decisions are at risk. Milestones should be quantitative, measurable, and realistic to regulatory steps and patient recruitment logistics.

Critical content areas explicitly called out:

• A clear rationale for choosing the proposed device and target patient population.
• Description of stimulation or recording approach and why the device design is suited for this study.
• Clear timeline with milestones tied to enrollment, safety, and efficacy indicators.
• A technology translation plan that states how the project moves toward broader clinical use.
• A long-term patient care plan, especially around post-study handling such as device removal, revision, and care continuity.
• Data sharing and management plan aligned with NIH BRAIN Initiative data policy and 21st Century Cures context.
• Explicit neuroethics sections where required.

Why these are treated as mandatory

The NOFO treats several of these as required for completeness. For example, a missing milestone plan section, missing neuroethics content in human subjects sections, or missing required supporting letters can move an application outside responsive review. This is not theoretical; the NOFO language clearly marks several such requirements as non-negotiable.

Timeline, dates, and practical application strategy for 2026/2027 planning

The key dates from the announcement include at least one active future cycle for the near term:

• Due date in 2026 cycle: September 28, 2026 (5:00 PM local time of applicant organization)
• Review and council steps around spring 2027 in the posted cycle table
• Earliest start date around May 2027 (as per NOFO date table)
• Expiration date listed as September 29, 2026

The NOFO also has an earlier 2025 submission cycle listed in the same table. For current planning in May 2026, the September 2026 cycle is the relevant one to target.

Practical timing advice before submission

To avoid avoidable errors, teams often do this in reverse:

1. Work backwards from the 2026-09-28 due date and set internal internal deadlines 8 weeks before.
2. Reserve at least one week for registration verification because system registrations can take long and late completion is not accepted as excuse.
3. Leave 4-5 business days for NIH systems testing and error correction in ASSIST or institutional route.
4. Finalize letters of support and institutional legal/IP approvals at least 10 business days before submission because these are common bottlenecks.

Applying early is actively encouraged in the NOFO because it allows correction of late validation issues before the final clock. This matters because the NOFO combines heavy clinical/regulatory content with NIH-specific technical forms.

How funding and review usually work

Funding structure and support level

The NOFO identifies funds available and anticipated awards on an annual basis of around $10 million and expects 5 to 7 awards. This is meaningful in planning because it indicates portfolio-level competition and selectivity.

Budget behavior:

• Budgets should reflect actual need.
• NIH notes an informal ceiling expectation around $1.5 million direct costs/year.
• Total project period up to 5 years.
• No cost sharing is required.

Review model and what reviewers score first

This is peer-reviewed using NIH review process:

• Scientific and technical merit evaluated in Scientific Review Group.
• Primary emphasis on impact, significance, innovation, approach, feasibility, and team fit.
• NIH explicitly gives guidance on how to align with BRAIN priorities, including:
  • clear value to CNS knowledge
  • robust measurable milestones
  • strong technical and clinical translation path
• There is a focus on human subjects protections, recruitment quality, reproducibility, and whether data can translate to patient-centered outcomes.

Additional review considerations include intellectual property handling, team governance quality, and resource validity. In this NOFO, team structure is not a side issue: reviewers evaluate how teams are built and managed, not just the idea.

What reviewers look for in strong UH3 proposals

From the NOFO text, the strongest proposals usually do these things well:

1) Show a real clinical gap and specific device relevance

Reviewers look for clearly defined clinical targets and realistic endpoints. The NOFO expects candidates where the device can answer an important question and has immediate relevance to CNS treatment or diagnosis.

2) Demonstrate rigorous study architecture

Applications are scored on rigor and reproducibility: controls, sample size reasoning, data analysis and interpretation, inclusion criteria design, and a credible plan for reporting. For early device trials this often means predefining safety stopping rules and interpretation criteria.

3) Build explicit milestones linked to go/no-go decisions

Milestones must be measurable and tied to device development and regulatory progression. Vague milestones (“collect data,” “demonstrate feasibility”) are weaker unless they include quantifiable targets.

4) Address neuroethics and human subject protections

Because these are brain studies with potentially invasive procedures, the NOFO puts strong emphasis on neuroethical risk context, participant safety, privacy, and post-procedure care responsibilities.

5) Align with BRAIN data sharing and standards

A Data Management and Sharing Plan is not just a checklist box. The NOFO expects use of appropriate data standards and archives and periodic progress of sharing consistent with BRAIN Initiative expectations. Plans should be realistic, implementable, and compliant.

6) Clarify IP and partnership mechanics

The NOFO expects clear statements around IP ownership, licensing, and commercialization pathway. For partnered device programs, letters from private entities or transfer offices are key.

Common mistakes that reduce competitiveness

Even technically strong applications fail due to preventable errors. The most common are:

• Treating the milestone system as paperwork instead of program structure.
• Submitting attachments beyond page limits.
• Missing the requirement for a clear Neuroethics component when human subjects and potentially invasive technology are involved.
• Weak or generic needs assessment that does not demonstrate patient/clinician/caregiver input.
• Underestimating long-term patient care and follow-up obligations.
• Weak IRB/FDA readiness and unclear pre-IDE or IDE strategy.
• Assuming the BRAIN PPP is mandatory and ignoring alternative device pathways.
• Failing to complete registrations before pushing near submission.

Each of these can be fixed, but they take time and often delay the entire pipeline. This is exactly why NIH recommends early consultation.

Strategic preparation plan for applicants

A practical plan for teams starting now:

1) Confirm opportunity fit

Match your device maturity to this NOFO. If your data are strong and regulatory strategy is credible but full early feasibility evidence is still emerging, this is likely a better match than exploratory R01 or UG3-stage options.

2) Build a milestone architecture early

Use one timeline across R&R forms, human subjects forms, and attachments. Include:

• recruitment windows
• enrollment targets
• safety and data collection windows
• regulatory touchpoints (pre-submission, IDE updates)
• decision points and go/no-go criteria

3) Get your clinical governance stack ready

You need to show:

• PI and institutional support
• data safety and monitoring governance
• neuroethics support
• team management and steering roles

4) Coordinate with legal and tech transfer

The NOFO is explicit on IP strategy. Get licensing and ownership language aligned with collaborating entities before submission, and obtain required letters early.

5) Prepare external dependencies before submission

This includes device source agreements, trial support contracts, FDA communications logs, and data-sharing agreements. Many teams lose points when these dependencies are deferred to after submission.

Frequently asked questions

Is this opportunity still usable for 2027 planning?

Yes, based on the published schedule, there is a 2026 due cycle with an earliest start and council timeline in 2027. The page is still relevant for upcoming funding planning in this range.

Is this only for clinical trials?

No. The clinical trials flag is optional. Applications may include but are not required to be clinical trials as long as they align with the NOFO’s device translational goals.

Are foreign institutions eligible?

No. Non-domestic foreign organizations are not eligible. U.S. entities with foreign components can include some components as allowed by policy, but the applying organization must be domestic.

What are the expected financial totals?

The NOFO states expected total funding and estimated number of awards at approximately $10M per year for 5 to 7 projects, and indicates applications should usually not exceed about $1,500,000 direct costs per year.

Can businesses apply?

Yes, for-profit organizations and small businesses are eligible categories.

Quick compliance checklist

Use this checklist before hitting final submit:

• Organization registration in SAM, eRA Commons, Grants.gov complete and current
• Mechanism confirmed as UH3 for this opportunity
• Eligibility category confirmed (domestic organization)
• Gantt chart, IP Strategy, Needs Assessment uploaded and within page limits
• Neuroethics section included where human subjects are involved
• Milestone plan with measurable go/no-go criteria
• Data Management and Sharing Plan covers archive strategy and timeline
• Team Management Plan with clear roles and steering structure
• Letters of support obtained from transfer, collaborators, clinical leads, and relevant private partners
• Compliance check on line lengths, attachments, and mandatory sections in the Application Guide

Official sources and useful links

• Primary NOFO: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-022.html
• Program context and PPP details: NIH BRAIN Initiative pages linked from the NOFO
• NIH application instructions: NIH How to Apply - Application Guide
• eRA / Grants / NIH help channels listed in Section VII of the NOFO

Bottom line

This is a high-structure, high-accountability opportunity for teams that already have a translational neurotechnology pipeline and can operate at the interface of engineering, clinical execution, and NIH compliance. It is best viewed as a milestone-governed execution track for device programs that need to move from a validated prototype to clinical evidence with federal support and oversight.

If your team already has a defined CNS device, a realistic enrollment strategy, and institutional support for IDE-centered execution, this NOFO is one of the more concrete federal paths for early clinical translation in 2026/2027. If the project is still mainly preclinical, it is usually better to strengthen data and development readiness before competing here.